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The effect of recombinant human soluble thrombomodulin (TM-a) on acute liver failure (ALF) is unclear,
and we elucidated the effect of TM-a in lipopolysaccharide (LPS)/D-galactosamine (GalN)-induced ALF in
mice. Placebo (saline) or TM-a (100 mg/kg) was administered 1 h after LPS/GalN administration. Survival
rates were evaluated for 24 h after LPS/GalN administration. Plasma and liver samples were evaluated 1,
3, and 7 h after LPS/GalN administration. Survival rates were signiﬁcantly higher in the TM-a-treated
group than in the placebo group. A signiﬁcant augmentation of plasma high-mobility group box 1 protein
(HMGB1) was observed 7 h after LPS/GalN administration. In the TM-a-treated mice, plasma HMGB1 was
signiﬁcantly lower than in the placebo group. A signiﬁcant augmentation of hepatic nuclear factor (NF)-
kB p65 was observed in the placebo-treated group, whereas a signiﬁcant reduction, relative to placebo,
was observed in the TM-a-treated group. Hepatic expression of tumor necrosis factor (TNF)-a and
myeloperoxidase were signiﬁcantly increased in the placebo group, and were similarly signiﬁcantly
attenuated in the TM-a-treated group. TM-a treatment also produced a signiﬁcant attenuation of liver
neutrophil accumulation after LPS/GalN administration. Thus, TM-a may become a useful treatment
strategy for reducing the symptoms of ALF via the attenuation of LPS/GalN-induced HMGB1 levels.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute liver failure (ALF) is a characterized by a rapid loss of
hepatocyte function, and its major causes are viral infection,
autoimmune hepatitis, and drug allergy (1). ALF is associated with
high mortality in patients, and liver transplantation is the only
effective therapeutic strategy for attenuating ALF. ALF is typically
initiated by the activation of inﬂammatory cells such as macro-
phages, which release several inﬂammatory cytokines, resulting in
massive death of parenchymal hepatocytes (2).edicine, Graduate School of
i, Takatsuki 569-8686, Japan.
kai).
rmacological Society.
. Production and hosting by ElseCombined administration of lipopolysaccharide (LPS) and D-
galactosamine (GalN) has become an established method for
inducing ALF in experimental animals (3,4). LPS causes sinusoidal
injury and intrahepatic ﬁbrin deposition, which results in severe
liver dysfunction (5). GalN potentiates the toxic effects of LPS in the
liver through upregulation of toll-like receptor (TLR)-4 mRNA
expression. TLR-4 speciﬁcally binds LPS in the liver (6). GalN-
potentiated binding of LPS to TLR-4 in the liver promotes the acti-
vation of nuclear factor (NF)-kB, ultimately inducing the production
of proinﬂammatory cytokines such as tumor necrosis factor (TNF)-a
(7). Activation of NF-kB induces inﬂammation and apoptosis in the
liver and increases TNF-a production, which exacerbates the
inﬂammation (3). Consequently, the combined administration of
LPS and GalN has been shown to speciﬁcally induce liver injury via
activation of NF-kB and increased production of TNF-a (8).vier B.V. This is an open access article under the CC BY-NC-ND license (http://
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histone DNA-binding protein that has both nuclear and extra-
cellular functions (9). HMGB1 is secreted by necrotic and
damaged cells, and release of HMGB1 into the extracellular space
induces the production of proinﬂammatory cytokines such as
TNF-a, resulting in a vicious cycle in which activated cytokines
induce further release of HMGB1 (10,11). Upregulation of
HMGB1 has been shown to be a lethal late-phase mediator of
sepsis (12).
Thrombomodulin (TM) is a thrombin receptor on the surface of
endothelial cells and plays a crucial role in regulating coagulation
(13). Additionally, TM activates protein C, resulting in anti-
inﬂammatory effects such as the suppression of TNF-a via inhibi-
tion of macrophage activation (14). In the present study, we used
recombinant human soluble thrombomodulin (TM-a), which not
only binds to HMGB1 but also cleaves HMGB1 by forming a com-
plex with thrombin, resulting in attenuation of HMGB1-mediated
inﬂammation (15). TM-a has proven to be useful in treating
disseminated intravascular coagulation in clinic. In a rat LPS-
induced sepsis model, TM-a was shown to signiﬁcantly attenuate
the upregulation of plasma HMGB1 levels (16). However, the role of
TM-a in ALF remains unclear. In the present study, we evaluated the
effect of TM-a on survival rate in a mouse model of LPS/GalN-
induced ALF.
2. Materials and methods
2.1. Drugs
LPS (Escherichia coli, 0111:B4) and GalN were purchased from
Sigma (St. Louis, MO). TM-awas obtained from Asahi Kasei Pharma
Co. Ltd. (Tokyo, Japan).
2.2. Animal model
Eight-week-old male C57BL/6 mice (n¼ 84) were obtained from
Japan SLC (Shizuoka, Japan) and housed in a temperature-, hu-
midity-, and light-controlled room. The effect of TM-a on the sur-
vival rate over the 24 h period following administration (i.p.) of LPS
(4 mg/kg)/GalN (600 mg/kg) was evaluated by administering (s.c.)
TM-a (100 mg/kg) or placebo (saline) 1 h after LPS/GalN injection
(each group: n ¼ 20). Measurements of plasma and liver parame-
ters were taken before and 1, 3, and 7 h after LPS/GalN injection
(n¼ 6) to assess time-dependent changes. The effects of TM-awere
evaluated following administration (s.c.) of TM-a (100 mg/kg) or
placebo (saline) 1 h after LPS/GalN injection, and blood and liver
tissue were obtained at 7 h after LPS/GalN injection (n ¼ 8). Age-
matched normal mice were used as a control group (n ¼ 6). All
procedures involving animals were conducted in accordance with
the Guidelines for the Care and Use of Laboratory Animals at Osaka
Medical College.
2.3. Aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) activities in plasma
Plasma was separated from the blood samples by centrifuga-
tion at 3000 rpm for 15 min at 4 C. Measurements of plasma
activities of AST and ALT were performed by SRL Co. Ltd. (Tokyo,
Japan).
2.4. HMGB1 in plasma
HMGB1 in plasma was measured with an enzyme-linked
immunosorbent assay (ELISA) kit (Shino-test Co., Sagamihara,
Japan) according to the manufacturer's instructions.2.5. Active NF-kB p65 in liver
To measure NF-kB p65, nuclear proteins were isolated from
fresh mouse liver using an NF-kB p65 ELISA kit (NOVUS Biologicals,
Abingdon, UK) according to the manufacturer's instructions. Then,
NF-kB p65 was measured using the NF-kB p65 ELISA kit.
Protein concentrations of the nuclear fraction were assayed
using the bicinchoninic acid Protein Assay Reagent (Pierce, Rock-
ford, IL) with bovine serum albumin as the standard.
2.6. Real-time polymerase chain reaction (RT-PCR)
Liver total RNA was extracted using the Trizol reagent (Life
Technologies, Rockville, MD) and subsequently dissolved in RNase-
free water (Takara Bio Inc. Otsu, Japan). Total RNA (1 mg) was
transcribed into cDNAwith Superscript VIRO (Invitrogen, Carlsbad,
CA). Levels of mRNA were measured by RT-PCR on a LightCycler
with software (Roche Diagnostics, Tokyo, Japan) using TaqMan
ﬂuorogenic probes. Primers and probes for RT-PCR of TNF-a, mye-
loperoxidase (MPO), and 18S ribosomal RNA (rRNA) were designed
by Roche Diagnostics. The primers were as follows: 50-aggcgaa-
gattactgccaag-30 (forward) and 50-catggctatgaggtagagacagg-30
(reverse) for TNF-a, 50-ctgaatcctcgatggaatgg-30 (forward) and 50-
ccatggcccctacaatctt-30 (reverse) for MPO, and 50-gcaattattccccat-
gaacg-30 (forward) and 50-gggacttaatcaacgcaagc-30 (reverse) for 18S
rRNA. The probes were as follows: 50-agccccag-30 for TNF-a, 50-
ccaggagg-30 for MPO, and 50-ttcccagt-30 for 18S rRNA. mRNA levels
of TNF-a and MPO were normalized to that of 18S rRNA.
2.7. Histological analysis
The liver tissue specimens were ﬁxed with Carnoy's ﬁxative in
10% methanol overnight. The ﬁxed liver tissues were embedded in
parafﬁn, and then cut at a thickness of 5 mm. The sections were
mounted on silanized slides (Matsunami, Kishiwada, Japan) and
deparafﬁnized with xylene and ethanol. The severity of hepatic
histological changes was assessed using hematoxylin and eosin
(HE) staining.
The procedure for immunohistochemical analysis of MPO has
been previously described (17). Sections were incubated with anti-
MPO antibody (Abcam Inc. Cambridge, MA) followed by a reaction
with appropriate reagents from a streptavidin-biotin peroxidase kit
(Dako LSABkit; Dako Co., Carpinteria, CA) and 3-amino-9-
ethylcarbazole, which was used for color development. The sec-
tions were lightly counterstained with hematoxylin.
2.8. Statistical analysis
Data are expressed as the mean ± standard error of the mean
(SEM). Signiﬁcant differences among mean values of multiple
groups were evaluated using a one-way analysis of variance fol-
lowed by Fisher's test. The cumulative survival in each group was
determined using the KaplaneMeier method, and survival was
compared between groups with a log-rank test. Values of P < 0.05
were considered statistically signiﬁcant.
3. Results
3.1. Effect of TM-a on survival rate after LPS/GalN administration
Twenty-four hours after LPS/GalN administration, the survival
rates were 15% and 55% in the placebo- and TM-a-treated groups,
respectively (Fig. 1). However, additional mortality was not
observed in either group after 24 h (Fig. 1). The survival rates
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Fig. 1. Cumulative percent survival following LPS/GalN administration in placebo (solid
line) and TM-a (broken line) treated animals. The difference in percent survival be-
tween placebo- and TM-a-treated animals was statistically signiﬁcant (KaplaneMeier
analysis followed by log rank test; P < 0.01; n ¼ 20).
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different (Fig. 1).3.2. Effect of TM-a on AST and ALT activities in plasma after LPS/
GalN administration
Time courses of AST and ALT activities in plasma after LPS/GalN
administration are shown in Fig. 2A and C. Both AST and ALT ac-
tivities in plasma were not signiﬁcantly altered until 3 h after LPS/
GalN administration, compared with the pre-administration
plasma levels; however, activities were signiﬁcantly increased at
7 h (Fig. 2A and C).
To evaluate the effect of TM-a on the activity of AST and ALT in
plasma, we administered TM-a 1 h after LPS/GalN treatment and
evaluated activity at 7 h, when signiﬁcant increases in post-LPS/
GalN activities were observed. Both AST and ALT activities were
signiﬁcantly lower in the TM-a-treated group compared to the
placebo-treated group (Fig. 2B and D).A
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Fig. 2. Time course of plasma AST (A) and ALT (C) activities before (Pre) and 1, 3, and 7 h after
pre-administration (A and C). Plasma AST (B) and ALT (D) activities in control and placebo- or
(n ¼ 8) (B and D). **P < 0.01 vs. placebo-treated group (B and D).3.3. Effect of TM-a on HMGB1 in plasma after LPS/GalN
administration
Plasma HMGB1 tended to be higher 3 h after LPS/GalN admin-
istration, but did not reach signiﬁcance (Fig. 3A). However, a sig-
niﬁcant increase in plasma HMGB1 was observed at 7 h (Fig. 3A).
The signiﬁcant increase in HMGB1 observed in the placebo-treated
group 7 h after LPS/GalN administration was signiﬁcantly attenu-
ated by TM-a treatment (Fig. 3B).
3.4. Effect of TM-a on NF-kB p65 in liver after LPS/GalN
administration
A signiﬁcant increase in liver NF-kB p65 was observed 1, 3, and
7 h after LPS/GalN administration compared with pre-
administration level (Fig. 4A). TM-a treatment signiﬁcantly atten-
uated NF-kB p65 in liver compared with the placebo-treated group
7 h after LPS/GalN administration (Fig. 4B).
3.5. Effects of TM-a on hepatic TNF-a and MPO gene expression
after LPS/GalN administration
Hepatic gene expression of TNF-a was signiﬁcantly higher 1 h
after LPS/GalN administration compared with the pre-
administration level (Fig. 5A). Augmented TNF-a gene expression
was signiﬁcantly attenuated in the TM-a-treated group (Fig. 5B).
Hepatic MPO gene expression was not signiﬁcantly different up
to 3 h after LPS/GalN administration compared with the pre-
administration level, while a signiﬁcant augmentation of MPO
gene expressionwas observed at 7 h (Fig. 5C). MPO gene expression
was signiﬁcantly attenuated by TM-a treatment (Fig. 5D).
3.6. Effects of TM-a on MPO-positive cell numbers after LPS/GalN
administration
Representative images of HE-stained liver sections from
control, placebo-, and TM-a-treated mice 7 h after LPS/GalN
administration are shown in Fig. 6A. Numerous necrotic
lesions were observed in the placebo-treated group; however,
these lesions were clearly reduced in the TM-a-treatedB
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Fig. 3. Time course of plasma HMGB1 levels before (Pre) and 1, 3, and 7 h after LPS/GalN administration (A). Values represent mean ± SEM (n ¼ 6) (A). **P < 0.01 vs. pre-
administration (A). Plasma HMGB1 levels in control and placebo- or TM-a-treated animals 7 h after LPS/GalN administration (B). Values represent mean ± SEM (n ¼ 8) (B).
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Fig. 4. Time course of hepatic NF-kB p65 before (Pre) and 1, 3, and 7 h after LPS/GalN administration (A). Values represent mean ± SEM (n ¼ 6) (A). *P < 0.05 vs. pre-administration
(A). Hepatic NF-kB p65 levels in control and placebo- or TM-a-treated animals 7 h after LPS/GalN administration (B). Values represent mean ± SEM (n ¼ 8) (B). *P < 0.05 and
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Fig. 5. Time course of hepatic gene expression of TNF-a (A) and MPO (C) before (Pre) and 1, 3, and 7 h after LPS/GalN administration. Values represent mean ± SEM (n ¼ 6) (A and C).
*P < 0.05 and **P < 0.01 vs. pre-administration (A and C). Hepatic gene expression of TNF-a (B) and MPO (D) in control and placebo- or TM-a-treated animals 7 h after LPS/GalN
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nostained with anti-MPO antibody from control, placebo-, and
TM-a-treated mice 7 h after LPS/GalN administration are
shown in Fig. 6A.The number of MPO-positive cells was signiﬁcantly higher in the
placebo-treated group than in the control group 7 h after LPS/GalN
administration, but was signiﬁcantly attenuated in the TM-a-
treated group (Fig. 6B).
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Fig. 6. Representative images of HE-stain (upper images) and MPO-positive cells (middle and bottom images) in the liver sections from control, placebo-, and TM-a-treated mice 7 h
after LPS/GalN administration (A). The original magniﬁcation was 100; scale bars are 100 mm (A: upper and middle images). The original magniﬁcation was 400; scale bars are
50 mm (A: lower images). MPO-positive cells in control, placebo-, and TM-a-treated animals 7 h after LPS/GalN administration (B). Values represent mean ± SEM (n ¼ 8). **P < 0.01
vs. placebo-treated group.
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In the present study, we demonstrated for the ﬁrst time that
delayed (1 h post-LPS/GalN) administration of TM-a signiﬁcantly
reduced liver injury as well as survival rate in LPS/GalN-induced
ALF. The importance of TNF-a has been demonstrate in the path-
ogenesis of ALF after LPS/GalN administration (4,18), and we
observed a signiﬁcant augmentation of hepatic TNF-a gene
expression 1 h after LPS/GalN administration. LPS is potentiated by
GalN in liver and immediately triggers the TLR-4 signaling pathway
in macrophages, which activates NF-kB and results in the produc-
tion of proinﬂammatory cytokines such as TNF-a (7). TNF-a pro-
motes hepatic apoptosis via inﬂammation and oxidative stress (19).
Numerous papers have demonstrated that pretreatment with anti-
inﬂammatory agents and antioxidants ameliorates the damage
associated with liver injury and enhances the survival rate after
LPS/GalN administration via a reduction in TNF-a levels (4,18,20).
These ﬁndings illustrate the importance of the rapid elevation in
TNF-a levels in the pathogenesis of ALF after LPS/GalN adminis-
tration. However, the agents used in these previous studies were
administered before LPS/GalN administration to attenuate the rapid
elevation in TNF-a levels occurring after LPS/GalN administration.
Prior studies have not determined whether attenuation of the
initial increase in TNF-a levels after LPS/GalN administration is
necessary to prevent ALF. In the present study, we found that the
increases in both the activity of AST and ALTandmortality rate after
LPS/GalN administration were signiﬁcantly attenuated in TM-a-
treated mice, even though TM-a was administered 1 h after LPS/
GalN administration. These ﬁndings clearly demonstrate that
treatment with TM-a after LPS/GalN administration can ameliorate
liver injury and enhance survival in mice experiencing ALF, even in
the presence of elevated TNF-a levels.
A signiﬁcant elevation of hepatic TNF-a gene expression has
previously been observed 1 h after LPS/GalN administration (4,18).
Although the signiﬁcant elevation of TNF-a was not observed 3 h
after LPS/GalN administration, signiﬁcantly elevated levels were
once again observed at 7 h. Themechanism underlying the biphasic
elevation of TNF-a levels after LPS/GalN administration remains
unclear. The initial increase in TNF-a level 1 h after LPS/GalN
administration is thought to be dependent on direct stimulation of
TLR-4 by LPS in liver macrophages, which in turn promotes thesecretion of proinﬂammatory cytokines such as TNF-a, leading to
signiﬁcant necrosis of hepatocytes (21). HMGB1 is released by
necrotic and damaged cells (10,11), and the observed increase in
HMGB1 levels at 7 h in the present study may be indicative of
hepatic necrosis. In general, increased activity of AST and ALT re-
ﬂects liver damage, and the activity of these enzymes was
dramatically elevated 7 h after LPS/GalN administration. The sec-
ond peak in TNF-a levels, observed 7 h after LPS/GalN administra-
tion, may be closely related to elevated HMGB1 levels in damaged
liver. HMGB1 acts as an inﬂammatory signal that promotes the
production of inﬂammatory cytokines such as TNF-a via the acti-
vation of p38 mitogen-activated protein kinase (22). In contrast,
TNF-a may also induce the release of HMGB1 from damaged liver
cells (12). Treatment with anti-TNF-a antibodies has been shown to
ameliorate liver injury and increase the survival rate in mice in a
manner that corresponds with the reduction in HMGB1 levels after
LPS/GalN administration (23). On the other hand, in rats, treatment
with anti-HMGB1 antibodies also attenuates TNF-a expression after
LPS/GalN administration (24). In animal models, TM-a has been
shown to diminish HMGB1 activity (15,25). Therefore, an increase
in HMGB1 release from damaged liver cells may induce the pro-
duction of TNF-a, which in turn induces HMGB1 release 7 h after
LPS/GalN administration. Therefore, TM-a may interrupt the
destructive cycle of TNF-a and HMGB1, preventing the progression
of ALF.
In addition to the increased inﬂammation and oxidative stress
during the acute phase of LPS/GalN-induced damage, TNF-a con-
tributes to neutrophil accumulation in the liver, which causes
massive hepatocyte necrosis during the late phase pathology after
LPS/GalN administration (25). Furthermore, HMGB1 also induces
the accumulation of neutrophils through the upregulation of
adhesionmolecules, such as intercellular adhesionmolecule-1 (26).
The accumulation of neutrophils may be involved in the accelera-
tion of late-phase ALF after LPS/GalN administration. In the present
study, a signiﬁcant increase in MPO activity was observed 7 h after
LPS/GalN administration. Although monocytes/macrophages are
fewer in number compared with neutrophils, monocytes/macro-
phages also contain MPO-positive granules (27). In the present
study, the number of MPO-positive cells increased after LPS/GalN
injection, and this increase was thought to be composed in part of
monocytes/macrophages. MPO is known to induce inﬂammation
W. Osumi et al. / Journal of Pharmacological Sciences 129 (2015) 233e239238and oxidative stress, leading to hepatic necrosis (28). In a rat
monocrotaline-induced sinusoidal obstruction syndrome model,
TM-a was shown to increase the survival rate after monocrotaline
administration due to attenuation of hepatic high-mobility group
box 1 (HMGB1) protein levels, MPO activity, and neutrophil accu-
mulation, all of which were signiﬁcantly augmented 6 h after
monocrotaline administration (29). HMGB1 was shown to promote
the recruitment of neutrophils (but not macrophages) into necrotic
liver tissues in mice, and attenuation of neutrophils (but not mac-
rophages) was observed in mice in which the gene encoding
HMGB1 was deleted (30). Therefore, the attenuation of MPO-
positive cells by TM-a may primarily involve a decrease in the
accumulation of neutrophils. However, to the best of our knowl-
edge, it remains unclear whether neutrophil-neutralizing anti-
bodies or neutrophil extracellular traps directly protect against
liver injury after LPS/GalN injection. Further studies will be needed
to investigate the relationship between neutrophil attenuation and
liver protection in ALF.
Activation of NF-kB is triggered by many factors, including LPS
and TNF-a. The binding of LPS by TLR-4 induces translocation from
the cytoplasm to the nucleus, where TLR-4 binds to NF-kB promotor
sites and activates transcription of TNF-a (31). The binding TNF-a to
its main receptor TNF-R1 also induces nuclear translocation and
transcriptional activation of NF-kB-dependent target genes (8). NF-
kB activity is controlled by a family of cytoplasmic inhibitory
molecules (I-kBs), and the p65:p50 NF-kB heterodimer is formed
after dissociation from I-kBa, which is degraded by the 26S pro-
teasome (8,32). The p65:p50 heterodimer is a major NF-kB DNA
binding complex induced by LPS and TNF-a, and p65 has been used
a major protein to monitor NF-kB activation. In the present study,
we also measured NF-kB p65 in liver tissues, and observed a sig-
niﬁcant increase in NF-kB even 1 h after LPS/GalN administration.
While the increase in NF-kB p65 continued to be observed for up to
7 h, the levels were signiﬁcantly attenuated by post-treatment with
TM-a. In rats, post-treatment with anti-HMGB1 antibodies after
LPS/GalN administration signiﬁcantly attenuated LPS/GalN-
induced late-phase levels of both TNF-a and NF-kB p65 (24). In
the present study, post-treatment with TM-a attenuated not only
HMGB1 levels, but also TNF-a and NF-kB p65 levels. Thus, the
mechanism underlying the beneﬁcial effect produced by post-
treatment with TM-a after LPS/GalN administration may be
closely related to the attenuation of LPS/GalN-induced late-phase
elevation of HMGB1.
In the present study, we evaluated each parameter in mice
administered TM-a at a dose of 100mg/kg (s.c.). As indicated above,
survival rates of 20 and 30% 24 h after LPS/GalN administration
were observed in mice administered TM-a (s.c.) at doses of 10 and
30 mg/kg, respectively, and no signiﬁcant difference was observed
compared with placebo-treated mice (survival rate of 15%). At a
100mg/kg dose of TM-a, the survival ratewas 55%, and a signiﬁcant
difference was observed compared with placebo-treated mice, as
shown in Fig. 1. A signiﬁcant increase in survival rate (60%)
compared with placebo was also observed at a TM-a (s.c.) dose of
200 mg/kg, but no signiﬁcant difference was observed between
mice receiving a TM-a (s.c.) dose of 100 or 200 mg/kg (data not
shown). Therefore, we selected a TM-a dose of 100 mg/kg for
evaluation of the various parameters. On the other hand, previous
papers have reported anti-inﬂammatory effects of TM-a at lower
doses. For example, 1 mg/kg of TM-a (i.v.) showed a signiﬁcant
effect in preventing lung injury in a rat model of LPS-induced
systemic inﬂammation (16), and 3 mg/kg of TM-a (i.v.) showed a
signiﬁcant effect in preventing liver damage in a rat model of
monocrotaline-induced sinusoidal obstruction syndrome (29). In a
mouse heat stroke model, signiﬁcant amelioration of liver injury
was observed with administration of 1 mg/kg of TM-a (i.p) (33).Although it is unclear why higher doses were required in the pre-
sent study compared with previous studies, the route of adminis-
tration (e.g., subcutaneous) may have affected our results. It can be
difﬁcult to achieve high blood concentrations of high-molecular-
weight substances such as TM-a (molecular weight approxi-
mately 64,000 Da) via subcutaneous injection, and this may have
played a role in our study. Another possibility is that the patho-
genesis of the animal model we used differs from that of other
models.
In conclusion, TM-a post-treatment attenuated liver damage
and improved survival rates following LPS/GalN-induced ALF in
mice, even when the levels of the proinﬂammatory cytokine TNF-a
were elevated. The mechanism underlying these effects of TM-a
may be mediated by the attenuation of LPS/GalN-induced HMGB1
levels during the late phase.
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